Bench-to-bedside review: Vasopressin in the management of septic shock

Critical Care

Volumn 15, Issue 4, 2011, Pages

  Russell, James A ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYPERTENSIVE FACTOR; NORADRENALIN; VASOPRESSIN; VASOPRESSIN RECEPTOR; HEMOSTATIC AGENT; VASOPRESSIN DERIVATIVE;

BLOOD PRESSURE MEASUREMENT; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ARREST; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LOW DRUG DOSE; MESENTERY DISEASE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SKIN NECROSIS; STATISTICAL SIGNIFICANCE; INTENSIVE CARE UNIT; METABOLISM;

HEMOSTATICS; HUMANS; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; VASOPRESSINS;

EID: 80052781572     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8224     Document Type: Review

References (142)

1. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994, 269:3304-3310.
2. Thibonnier M, Graves MK, Wagner MS, Chatelain N, Soubrier F, Corvol P, Willard HF, Jeunemaitre X. Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J Mol Cell Cardiol 2000, 324:557-564.
3. Berrada K, Plesnicher CL, Luo X, Thibonnier M. Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. J Biol Chem 2000, 275:27229-27237.
4. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 1999, 17:673-678. 10.1097/00004872-199917050-00011, 10403611.
5. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endotheliumdependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993, 103:1241-1245. 10.1378/chest.103.4.1241, 8131474.
6. Russ RD, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 1992, 262(3 Pt 2):H743-H747.
7. Sai Y, Okamura T, Amakata Y, Toda N. Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Eur J Pharmacol 1995, 282:235-241. 10.1016/0014-2999(95)00343-J, 7498282.
8. Kim SJ, Young LJ, Gonen D, Veenstra-VanderWeele J, Courchesne R, Courchesne E, Lord C, Leventhal BL, Cook EH, Insel TR. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 2002, 7:503-507. 10.1038/sj.mp.4001125, 12082568.
9. Knafo A, Israel S, Darvasi A, Bachner-Melman R, Uzefovsky F, Cohen L, Feldman E, Lerer E, Laiba E, Raz Y, Nemanov L, Gritsenko I, Dina C. Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav 2008, 7:266-275. 10.1111/j.1601-183X.2007.00341.x, 17696996.
10. Bucher M, Hobbhahn J, Taeger K, Kurtz A. Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002, 282:R979-R984.
11. Roth BL, Spitzer JA. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987, 252(5 Pt 1):E699-E702.
12. Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007, 35:2337-2343. 10.1097/01.CCM.0000281861.72907.17, 17944022.
13. Antoni FA, Holmes MC, Makara GB, Karteszi M, Laszlo FA. Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 1984, 5:519-522. 10.1016/0196-9781(84)90080-9, 6089144.
14. Hernando F, Schoots O, Lolait SJ, Burbach JP. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001, 142:1659-1668. 10.1210/en.142.4.1659, 11250948.
15. Lolait SJ, Stewart LQ, Jessop DS, Young WS, O'Carroll AM. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007, 148:849-856. 2040022, 17122081.
16. de Keyzer Y, Lenne F, Auzan C, Jegou S, Rene P, Vaudry H, Kuhn JM, Luton JP, Clauser E, Bertagna X. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996, 97:1311-1318. 10.1172/JCI118547, 507185, 8636444.
17. O'Connor PM, Cowley AW. Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. Am J Physiol Renal Physiol 2007, 293:F526-F532. 10.1152/ajprenal.00052.2007, 17507604.
18. Park F, Zou AP, Cowley AW. Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla. Hypertension 1998, 32:896-901.
19. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007, 35:2375-2382. 10.1097/01.CCM.0000284508.05247.B3, 17944029.
20. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factorcleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006, 107:528-534. 10.1182/blood-2005-03-1087, 16189276.
21. Schmidt C, Hocherl K, Kurt B, Bucher M. Role of nuclear factor-κBdependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture-induced circulatory failure. Crit Care Med 2008, 36:2363-2372. 10.1097/CCM.0b013e318180b51d, 18596633.
22. Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G. Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 2004, 65:54-62. 10.1111/j.1523-1755.2004.00378.x, 14675036.
23. Qahwash IM, Cassar CA, Radcliff RP, Smith GW. Bacterial lipopolysaccharideinduced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers. Endocrine 2002, 18:13-20. 10.1385/ENDO:18:1:13, 12166619.
24. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC. Human vascular endothelial cells express oxytocin receptors. Endocrinology 1999, 140:1301-1309. 10.1210/en.140.3.1301, 10067857.
25. Gutkowska J, Jankowski M, Mukaddam-Daher S, McCann SM. Oxytocin is a cardiovascular hormone. Braz J Med Biol Res 2000, 33:625-633.
26. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR. Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care 2009, 13:R98. 10.1186/cc7930, 2717470, 19549333.
27. Mori M, Tsushima H, Matsuda T. Antidiuretic effects of ATP induced by microinjection into the hypothalamic supraoptic nucleus in water-loaded and ethanol-anesthetized rats. Jpn J Pharmacol 1994, 66:445-450. 10.1254/jjp.66.445, 7723221.
28. Guo W, Sun J, Xu X, Bunstock G, He C, Xiang Z. P2X receptors are differentially expressed on vasopressin- and oxytocin-containing neurons in the supraoptic and paraventricular nuclei of rat hypothalamus. Histochem Cell Biol 2009, 131:29-41. 10.1007/s00418-008-0493-9, 18787835.
29. Knott TK, Velazquez-Marrero C, Lemos JR. ATP elicits inward currents in isolated vasopressinergic neurohypophysial terminals via P2X2 and P2X3 receptors. Pflugers Arch 2005, 450:381-389. 10.1007/s00424-005-1471-x, 15988588.
30. Knott TK, Marrero HG, Custer EE, Lemos JR. Endogenous ATP potentiates only vasopressin secretion from neurohypophysial terminals. J Cell Physiol 2008, 217:155-161. 10.1002/jcp.21485, 18481265.
31. Song Z, Vijayaraghavan S, Sladek CD. ATP increases intracellular calcium in supraoptic neurons by activation of both P2X and P2Y purinergic receptors. Am J Physiol Regul Integr Comp Physiol 2007, 292:R423-R431.
32. Song Z, Gomes DA, Stevens W. Role of purinergic P2Y1 receptors in regulation of vasopressin and oxytocin secretion. Am J Physiol Regul Integr Comp Physiol 2009, 297:R478-R484. 10.1152/ajpregu.00163.2009, 19515986.
33. Troadec JD, Thirion S, Nicaise G, Lemos JR, Dayanithi G. ATP-evoked increases in [Ca2+]i and peptide release from rat isolated neurohypophysial terminals via a P2X2 purinoceptor. J Physiol 1998, 511(Pt 1):89-103. 2231092, 9679166.
34. Buller KM, Khanna S, Sibbald JR, Day TA. Central noradrenergic neurons signal via ATP to elicit vasopressin responses to haemorrhage. Neuroscience 1996, 73:637-642. 10.1016/0306-4522(96)00156-X, 8809784.
35. Sperlagh B, Mergl Z, Juranyi Z, Vizi ES, Makara GB. Local regulation of vasopressin and oxytocin secretion by extracellular ATP in the isolated posterior lobe of the rat hypophysis. J Endocrinol 1999, 160:343-350. 10.1677/joe.0.1600343, 10076181.
36. Kapoor JR, Sladek CD. Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. J Neurosci 2000, 20:8868-8875.
37. Troadec JD, Thirion S. Multifaceted purinergic regulation of stimulussecretion coupling in the neurohypophysis. Neuro Endocrinol Lett 2002, 23:273-280.
38. Xiang Z, He C, Burnstock G. P2X5 receptors are expressed on neurons containing arginine vasopressin and nitric oxide synthase in the rat hypothalamus. Brain Res 2006, 1099:56-63. 10.1016/j.brainres.2006.04.126, 16765918.
39. Sladek CD, Song Z. Regulation of vasopressin release by co-released neurotransmitters: mechanisms of purinergic and adrenergic synergism. Prog Brain Res 2008, 170:93-107.
40. Gomes DA, Song Z, Stevens W, Sladek CD. Sustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors. Am J Physiol Regul Integr Comp Physiol 2009, 297:R940-R949. 10.1152/ajpregu.00358.2009, 2763823, 19625689.
41. Espallergues J, Solovieva O, Techer V, Bauer K, Alonso G, Vincent A, Hussy N. Synergistic activation of astrocytes by ATP and norepinephrine in the rat supraoptic nucleus. Neuroscience 2007, 148:712-723. 10.1016/j.neuroscience.2007.03.043, 17693027.
42. Song Z, Sladek CD. Does conversion of ATP to adenosine terminate ATP-stimulated vasopressin release from hypothalamo-neurohypophyseal explants?. Brain Res 2005, 1047:105-111. 10.1016/j.brainres.2005.04.025, 15893296.
43. Cha SH, Sekine T, Endou H. P2 purinoceptor localization along rat nephron and evidence suggesting existence of subtypes P2Y1 and P2Y2. Am J Physiol 1998, 274(6 Pt 2):F1006-F1014.
44. Wildman SS, Boone M, Peppiatt-Wildman CM, Contreras-Sanz A, King BF, Shirley DG, Deen PM, Unwin RJ. Nucleotides downregulate aquaporin 2 via activation of apical P2 receptors. J Am Soc Nephrol 2009, 20:1480-1490. 10.1681/ASN.2008070686, 2709676, 19423692.
45. Rieg T, Bundey RA, Chen Y, Deschenes G, Junger W, Insel PA, Vallon V. Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption. FASEB J 2007, 21:3717-3726. 10.1096/fj.07-8807com, 17575258.
46. Zenteno-Savin T, Sada-Ovalle I, Ceballos G, Rubio R. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol 2000, 410:15-23. 10.1016/S0014-2999(00)00853-0, 11134652.
47. Wilson MF, Brackett DJ, Tompkins P, Benjamin B, Archer LT, Hinshaw LB. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 1981, 6:15-26.
48. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95:1122-1125.
49. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997, 25:1279-1282. 10.1097/00003246-199708000-00012, 9267938.
50. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31:1752-1758. 10.1097/01.CCM.0000063046.82359.4A, 12794416.
51. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002, 30:497-500. 10.1097/00003246-200203000-00001, 11990905.
52. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265.
53. Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 2009, 37:476-482. 10.1097/CCM.0b013e3181957532, 19114902.
54. Carnio EC, Moreto V, Giusti-Paiva A, Antunes-Rodrigues J. Neuro-immuneendocrine mechanisms during septic shock: role for nitric oxide in vasopressin and oxytocin release. Endocr Metab Immune Disord Drug Targets 2006, 6:137-142.
55. Correa PB, Pancoto JA, de Oliveira-Pelegrin GR, Carnio EC, Rocha MJ. Participation of iNOS-derived NO in hypothalamic activation and vasopressin release during polymicrobial sepsis. J Neuroimmunol 2007, 183:17-25. 10.1016/j.jneuroim.2006.10.021, 17173980.
56. Moreto V, Stabile AM, Antunes-Rodrigues J, Carnio EC. Role of hemeoxygenase pathway on vasopressin deficiency during endotoxemic shock-like conditions. Shock 2006, 26:472-476. 10.1097/01.shk.0000230301.86139.6a, 17047517.
57. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007, 28:219-226. 10.1097/SHK.0b013e318033e5da, 17515850.
58. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, Bergmann A, Tamm M, Christ-Crain M. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007, 37:145-152. 10.1111/j.1365-2362.2007.01762.x, 17217381.
59. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schwarz S, Hasibeder WR, Friesenecker BE, Dunser MW. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006, 91:4381-4386. 10.1210/jc.2005-2830, 16940457.
60. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker B, Mayr AG, Dunser MW. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006, 34:293-299. 10.1097/01.CCM.0000198528.56397.4F, 16424705.
61. Lin IY, Ma HP, Lin AC, Chong CF, Lin CM, Wang TL. Low plasma vasopressin/norepinephrine ratio predicts septic shock. Am J Emerg Med 2005, 23:718-724. 10.1016/j.ajem.2005.02.055, 16182977.
62. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AG, Friesenecker B. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005, 33:2659-2666. 10.1097/01.CCM.0000186749.34028.40, 16276194.
63. Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, Dunser MW. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007, 35:2280-2285. 10.1097/01.CCM.0000281853.50661.23, 17944015.
64. Lodha R, Vivekanandhan S, Sarthi M, Kabra SK. Serial circulating vasopressin levels in children with septic shock. Pediatr Crit Care Med 2006, 7:220-224. 10.1097/01.PCC.0000216414.00362.81, 16575349.
65. Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001, 29:1756-1760. 10.1097/00003246-200109000-00017, 11546979.
66. Nakajima Y, Baudry N, Duranteau J, Vicaut E. Effects of vasopressin, norepinephrine, and L-arginine on intestinal microcirculation in endotoxemia. Crit Care Med 2006, 34:1752-1757. 10.1097/01.CCM.0000218812.73741.6C, 16625119.
67. Knotzer H, Maier S, Dunser MW, Hasibeder WR, Hausdorfer H, Brandner J, Torgersen C, Ulmer H, Friesenecker B, Iannetti C, Pajik W. Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model. Intensive Care Med 2006, 32:170-174. 10.1007/s00134-005-2858-z, 16328220.
68. Leone M, Boyle WA. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006, 34:1126-1130. 10.1097/01.CCM.0000206466.56669.BE, 16484914.
69. Kang CH, Kim WG. The effect of vasopressin on organ blood flow in an endotoxin-induced rabbit shock model. J Invest Surg 2006, 19:361-369. 10.1080/08941930600985702, 17101605.
70. Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med 2003, 29:1020-1023.
71. Kienbaum P, Prante C, Lehmann N, Sander A, Jalowy A, Peters J. Alterations in forearm vascular reactivity in patients with septic shock. Anaesthesia 2008, 63:121-128. 10.1111/j.1365-2044.2007.05286.x, 18211441.
72. Russell JA. Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care 2007, 13:383-391. 10.1097/MCC.0b013e328263885e, 17599007.
73. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001, 93:7-13.
74. Dunser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002, 28:746-751. 10.1007/s00134-002-1265-y, 12107681.
75. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003, 107:2313-2319. 10.1161/01.CIR.0000066692.71008.BB, 12732600.
76. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001, 27:1416-1421. 10.1007/s001340101014, 11511958.
77. Malay MB, Ashton RC, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999, 47:699-703. 10.1097/00005373-199910000-00014, 10528604.
78. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-582. 10.1097/00000542-200203000-00011, 11873030.
79. Hiltebrand LB, Krejci V, Jakob SM, Takala J, Sigurdsson GH. Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology 2007, 106:1156-1167. 10.1097/01.anes.0000267599.02140.86, 17525591.
80. Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003, 31:1394-1398. 10.1097/01.CCM.0000059722.94182.79, 12771608.
81. Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A. Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 2008, 36:848-854. 10.1097/CCM.0B013E31816532BE, 18431272.
82. American College of Chest Physicians/Society of Critical Care Medicine Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine.
83. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992, 101:1481-1483. 10.1378/chest.101.6.1481, 1600757.
84. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
85. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
86. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124. 10.1056/NEJMoa071366, 18184957.
87. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169.
88. Hall LG, Oyen LJ, Taner CB, Cullinane DC, Baird TK, Cha SS, Sawyer MD. Fixeddose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004, 24:1002-1012. 10.1592/phco.24.11.1002.36139, 15338849.
89. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009, 37:811-818. 10.1097/CCM.0b013e3181961ace, 19237882.
90. Rabadan-Diehl C, Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998, 139:3220-3226. 10.1210/en.139.7.3220, 9645696.
91. Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, Traber DL, Westphal M. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007, 27:281-288. 10.1097/01.shk.0000235140.97903.90, 17304109.
92. Lauand F, Ruginsk SG, Rodrigues HL, Reis WL, de Castro M, Elias LL, Antunes-Rodrigues J. Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation. Neuroscience 2007, 147:247-257. 10.1016/j.neuroscience.2007.04.021, 17524563.
93. Pietranera L, Saravia F, Roig P, Lima A, De Nicola AF. Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology 2004, 80:100-110. 10.1159/000081314, 15475662.
94. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000, 96:23-29. 10.1016/S0167-0115(00)00196-8, 11102648.
95. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004, 113:302-309. 311433, 14722621.
96. Annane D. Vasopressin plus corticosteroids: the shock duo!. Crit Care Med 2009, 37:1126-1127. 10.1097/CCM.0b013e31819879c1, 19237927.
97. Dunser MW, Hasibeder WR, Wenzel V. Vasopressin in septic shock. N Engl J Med 2008, 358:2736. author reply 7-8.
98. Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW. Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 2004, 32:194-200. 10.1097/01.CCM.0000104201.62736.12, 14707579.
99. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003, 97:1756-1763. 10.1213/01.ANE.0000087039.60041.2E, 14633555.
100. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31:2646-2650. 10.1097/01.CCM.0000094260.05266.F4, 14605537.
101. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004, 22:314-319. 10.1097/01.shk.0000136097.42048.bd, 15377885.
102. Leone M, Boutiere-Albanese B, Valette S, Camoin-Jau L, Barrau K, Albanese J, Martin C, Dignat-George F. Cell adhesion molecules as a marker reflecting the reduction of endothelial activation induced by glucocorticoids. Shock 2004, 21:311-314. 10.1097/00024382-200404000-00004, 15179130.
103. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002, 359:1209-1210. 10.1016/S0140-6736(02)08225-9, 11955542.
104. Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005, 33:1897-1902. 10.1097/01.CCM.0000178182.37639.D6, 16148457.
105. Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003, 31:215-220. 10.1097/00003246-200301000-00033, 12545018.
106. Asfar P, Hauser B, Ivanyi Z, Ehrmann U, Kick J, Albicini M, Vogt J, Wachter U, Bruckner UB, Radermacher P, Bracht H. Low-dose terlipressin during longterm hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005, 33:373-380. 10.1097/01.CCM.0000152253.45901.FB, 15699842.
107. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004, 30:597-604. 10.1007/s00134-003-2094-3, 14673520.
108. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG. Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 2003, 31:1502-1508. 10.1097/01.CCM.0000063042.15272.84, 12771625.
109. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003, 29:301-308.
110. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006, 40:2170-2177. 10.1345/aph.1H373, 17148649.
111. Morelli A, Ertmer C, Lange M, Dunser M, Rehberg S, Van Aken H, Pietropaoli P, Westphal M. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008, 100:494-503. 10.1093/bja/aen017, 18308741.
112. Lange M, Ertmer C, Westphal M. Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008, 34:821-832. 10.1007/s00134-007-0946-y, 18066524.
113. Bernadich C, Bandi JC, Melin P, Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998, 27:351-356. 10.1002/hep.510270206, 9462630.
114. Forsling ML, Aziz LA, Miller M, Davies R, Donovan B. Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 1980, 85:237-244. 10.1677/joe.0.0850237, 7400711.
115. Fabian M, Forsling ML, Jones JJ, Pryor JS. The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. J Physiol 1969, 204:653-668. 1351579, 5824107.
116. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 1990, 16:307-314.
117. Klein M, Weksler N, Borer A, Koyfman L, Kesslin J, Gurman GM. Terlipressin facilitates transport of septic patients treated with norepinephrine. Isr Med Assoc J 2006, 8:691-693.
118. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial. J Gastroenterol Hepatol 2003, 18:152-156. 10.1046/j.1440-1746.2003.02934.x, 12542598.
119. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gulberg V, Sigal S, Teuber P. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368. 10.1053/j.gastro.2008.02.014, 18471513.
120. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, Terra C, Fabrega E, Arroyo V, Rhodes J, Gines P. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359. 10.1053/j.gastro.2008.02.024, 18471512.
121. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hebert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine 2009, 36:83-91.
122. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009, 13:R130. 10.1186/cc7990, 2750187, 19664253.
123. Rehberg S, Ertmer C, Kohler G, Spiegel HU, Morelli A, Lange M, Moll K, Schlack K, Van Aken H, Su F, Vincent JL, Westphal M. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009, 35:1286-1296. 10.1007/s00134-009-1470-z, 19360396.
124. Michel F, Thomachot L, David M, Nicaise C, Vialet R, Di Marco JN, Lagier P, Martin C. Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. Am J Emerg Med 2007, 25:863.e1-2. 10.1016/j.ajem.2007.02.019, 17870513.
125. Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Bone HG, Van Aken H, Traber DL, Westphal M. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007, 28:623-629.
126. Broking K, Lange M, Morelli A, Ertmer C, Aken HV, Luecke M, Rehberg S, Bowering N, Bone HG, Traber DL, Westphal M. Employing dobutamine as a useful agent to reverse the terlipressin-linked impairments in cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 2008, 29:71-77.
127. Ryckwaert F, Virsolvy A, Fort A, Murat B, Richard S, Guillon G, Colson PH. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009, 37:876-881. 10.1097/CCM.0b013e31819b8199, 19237891.
128. Ouattara A, Landi M, Le Manach Y, Lecomte P, Leguen M, Boccara G, Coriat P, Riou B. Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart. Anesthesiology 2005, 102:85-92. 10.1097/00000542-200501000-00016, 15618791.
129. Noguera I, Medina P, Segarra G, Martinez MC, Aldasoro M, Vila JM, Lluch S. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol 1997, 122:431-438. 10.1038/sj.bjp.0701397, 1564956, 9351498.
130. Urge J, Sincl F, Prochazka V, Urbanek K. Terlipressin-induced ventricular arrhythmia. Scand J Gastroenterol 2008, 43:1145-1148. 10.1080/00365520801905304, 18609153.
131. Siami S, Bailly-Salin J, Polito A, Porcher R, Blanchard A, Haymann JP, Laborde K, Maxime V, Boucly C, Carlier R, Annane D, Sharshar T. Osmoregulation of vasopressin secretion is altered in the postacute phase of septic shock. Crit Care Med 2010, 38:1962-1969.
132. Bauer SR, Aloi JJ, Ahrens CL, Yeh JY, Culver DA, Reddy AJ. Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: a retrospective cohort study. J Crit Care 2010, 25:362.e7-362.e11. 10.1016/j.jcrc.2009.10.005, 19926252.
133. Holt DB, Delaney RR, Uyehara CF. Effects of combination dobutamine and vasopressin therapy on microcirculatory blood flow in a porcine model of severe endotoxic shock. J Surg Res 2009, [Epub ahead of print].
134. Rehberg S, Ertmer C, Vincent JL, Spiegel HU, Köhler G, Erren M, Lange M, Morelli A, Seisel J, Su F, Van Aken H, Traber DL, Westphal M. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock. Crit Care Med 2010, 38:2016-2023.
135. Nakada T, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR, Thair SA, Hirasawa H, Oda S, Walley KR. Leucyl/cystinyl aminopeptidase (LNPEP) gene variants in septic shock. Chest 2011, 139:1042-1049. 10.1378/chest.10-2517, 21330387.
136. Wagener G, Kovalevskaya G, Minhaz M, Mattis F, Emond JC, Landry DW. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2010,
137. Rehberg S, Ertmer C, Lange M, Morelli A, Whorton E, Dünser M, Strohhäcker AK, Lipke E, Kampmeier TG, Van Aken H, Traber DL, Westphal M. Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study. Crit Care 2010, 14:R200. 10.1186/cc9320, 21054850.
138. Sharshar T, Carlier R, Blanchard A, Feyde A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002, 30:497-500. 10.1097/00003246-200203000-00001, 11990905.
139. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31:1752-1758. 10.1097/01.CCM.0000063046.82359.4A, 12794416.
140. Le Clerc F, Walter-Nicolet E, Leteurtre S, Noizet O, Sadik A, Cremer R, Fourier C. Admission plasma vasopressin levels in children with meningococcal septic shock. Intensive Care Med 2003, 29:1339-1344. 10.1007/s00134-003-1868-y, 12856123.
141. Kruger S, Ewig S, Kunde J. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pretreatment. Results from the German competence network (CAPNETZ). J Antimicrob Chemother 2009, 64:159-162. 10.1093/jac/dkp148, 19403654.
142. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008, 34:518-522. 10.1007/s00134-007-0955-x, 2244699, 18080111.